A Review of the Safety and Adverse Event Profile of the Fixed-Ratio Combination of Insulin Glargine and Lixisenatide

INTRODUCTION: iGlarLixi is a titratable, fixed-ratio combination of insulin glargine (100 units/mL) and lixisenatide (33 μg/mL). This review evaluates the overall safety and adverse event (AE) profile of iGlarLixi in patients with type 2 diabetes. METHODS: We collated patient-level data from the pha...

Descripción completa

Detalles Bibliográficos
Autores principales: Frias, Juan P., Dex, Terry, Roberts, Michelle, Kaplan, Allen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349286/
https://www.ncbi.nlm.nih.gov/pubmed/30539523
http://dx.doi.org/10.1007/s13300-018-0547-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349286/
https://www.ncbi.nlm.nih.gov/pubmed/30539523
http://dx.doi.org/10.1007/s13300-018-0547-5

Ejemplares similares